Remarkable results for dostarlimab in rectal cancer subset

Dostarlimab, an anti–PD-1 monoclonal antibody marketed by GSK (LSE: GSK) under the brand name Jemperli, has shown impressive results in mismatch repair–deficient stage II or III rectal adenocarcinoma.

Findings from a prospective Phase II study were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the New England Journal of Medicine.

During this research, dostarlimab was administered every three weeks for six months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma.